drugset / Trial / NCT01770613

A Study of Allogeneic Mesenchymal Bone Marrow Cells in Subjects With ST Segment Elevation Myocardial Infarction (STEMI)

NCT01770613

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the safety and tolerability of human allogeneic mesenchymal bone marrow cells (aMBMC) administered intravenously to subjects with ST Segment Elevation Myocardial Infarction (STEMI).

Timeline

Start
2013-02
Primary completion
2016-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Subject mesenchymal stem cells Cell therapy Intravenous